Identifying biomarkers to guide immunotherapy treatment of cancer of unknown primary.
Linda R Mileshkin, Atara Posner, Andrew Pattison, Shiva Balachander, Dariush Etemadmoghadam, Andrew Fellowes, Hui Li Wong, Eryn Dow, Anna DeFazio, Bo Gao, Christos Stelios Karapetis, Madhu Sudan Singh, Ian M Collins, Christopher Steer, Mark Andrew Warren, Narayan Karanth, David Bowtell, Owen WJ Prall, Richard Tothill
Journal of Clinical Oncology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2020
e15252 Background: Cancer of unknown primary (CUP) is a metastatic cancer where the primary tissue of origin (ToO) evades detection despite extensive clinical investigation. Recent approaches to the management of CUP have involved gene-expression profiling to resolve the likely ToO and mutational profiling to identify targeted treatments. Current evidence is that both of these methods can have some clinical benefit but only in a minority of cases. Immunotherapy may also be effective in CUP, but clinical trials looking at this are yet to report and the best way to select patients who may benefit is uncertain. Methods: Through a national cohort study called Solving Unknown Primary Cancer (SUP..View full abstract